Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.36 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.36 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9530409 | 0.73 | HDAC3 (0.38) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL9414145 | 0.69 | GPR35 (0.40) | GPR35HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL22832568 | 0.69 | — | — | |
| SCHEMBL31296983 | 0.68 | GPR35 (0.39) | GPR35HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL22845159 | 0.68 | — | — | |
| SCHEMBL15110885 | 0.67 | CYP11B1 (0.32) | — | |
| SCHEMBL18546540 | 0.66 | GPR35 (0.34) | GPR35HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL9534654 | 0.66 | CA2 (0.45) | — | |
| SCHEMBL2041571 | 0.66 | KDM4E (0.42) | GAAALDH1A1POLB | |
| SCHEMBL9414150 | 0.66 | GPR35 (0.37) | GPR35HDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542270-B2 | BCKDK inhibitors | PFIZER INC. (US) | 2023-01-03 | — | — | US | disclosed |
| EP-3990461-A1 | THIENO[3,2-B]THIOPHENE-2-CARBOXYLIC ACID COMPOUNDS HAVING BCKDK INHIBITING ACTIVITY | Pfizer Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| US-11059833-B2 | BCKDK inhibitors | PFIZER INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-20210087204-A1 | BCKDK INHIBITORS | PFIZER INC. (US) | 2021-03-25 | — | — | US | disclosed |
| US-20210024536-A1 | BCKDK INHIBITORS | PFIZER INC. (US) | 2021-01-28 | — | — | US | disclosed |
| WO-2020261205-A1 | THIENO[3,2-B]THIOPHENE-2-CARBOXYLIC ACID COMPOUNDS HAVING BCKDK INHIBITING ACTIVITY | PFIZER INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020261205-A1 | THIENO[3,2-B]THIOPHENE-2-CARBOXYLIC ACID COMPOUNDS HAVING BCKDK INHIBITING ACTIVITY | PFIZER INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| EP-0375320-B1 | Substituted thieno(3,2-B) thiophene-2-sulfonamides as topically active carbonic anhydrase inhibitors | MERCK & CO INC (US) | 1993-11-24 | — | — | EP | disclosed |
| EP-0375320-A1 | Substituted thieno(3,2-B) thiophene-2-sulfonamides as topically active carbonic anhydrase inhibitors | MERCK & CO. INC. (US) | 1990-06-27 | — | — | EP | disclosed |
| US-4876271-A | GLAUCOMA | MERCK & CO., INC. (US) | 1989-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087204-A1 | BCKDK INHIBITORS | BCKDK, PDK4, PDK3 | GPR35 3710/4885HDAC3 723/4885HDAC4 1321/4885 |
| US-11059833-B2 | BCKDK inhibitors | BCKDK, PDK4, PDK3 | GPR35 3710/4885HDAC3 723/4885HDAC4 1321/4885 |
| US-11542270-B2 | BCKDK inhibitors | BCKDK, PDK4, PDK3 | GPR35 3710/4885HDAC3 723/4885HDAC4 1321/4885 |
| US-20210024536-A1 | BCKDK INHIBITORS | BCKDK, PDK4, PDK3 | GPR35 3710/4885HDAC3 723/4885HDAC4 1321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.